Despite the phase II failure, Chemocentryx is pushing on in hidradenitis suppurativa.
A mid-stage clinical failure raises more doubts about Galapagos’s pipeline and the wisdom of Gilead’s $5bn deal last year.
As the company is punished for its failure to diversify, could it be forced into making an acquisition?
An NIAID-sponsored study of a Lilly antibody has been paused for possible toxicity, prompting speculation over the cause of the problem.
Details are scant about the “unexplained illness” seen with Johnson & Johnson’s Covid-19 vaccine, but the news puts another dent in public confidence.
Intercept’s woes have continued as a possible new liver toxicity signal was buried in a regulatory filing. What could this mean?